Literature DB >> 16706268

Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.

S Vincent Rajkumar1, Angela Dispenzieri, Robert A Kyle.   

Abstract

The spectrum of plasma cell disorders is broad. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma are asymptomatic disorders characterized by monoclonal plasma cell proliferation in the bone marrow in the absence of end-organ damage. Waldenström macroglobulinemia typically involves an ontogenically less mature lymphoplasmacytic bone marrow cell and is characterized by secretion of a monoclonal IgM protein. Solitary plasmacytoma is the only known potentially curable plasma cell disorder. Finally, AL (immunoglobulin light chain) amyloidosis and POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome are disorders characterized by low tumor burden but profound multisystemic disease. Updated diagnostic criteria for these disorders, risk stratification models to determine prognosis, and the current management of these diverse entitles are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706268     DOI: 10.4065/81.5.693

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  43 in total

1.  Aspergillus fumigatus scleritis associated with monoclonal gammopathy of undetermined significance.

Authors:  Dong Hyun Jo; Joo Youn Oh; Mee Kum Kim; Jang Won Heo; Jin Hak Lee; Won Ryang Wee
Journal:  Korean J Ophthalmol       Date:  2010-06-05

Review 2.  Narrative review: the systemic capillary leak syndrome.

Authors:  Kirk M Druey; Philip R Greipp
Journal:  Ann Intern Med       Date:  2010-07-20       Impact factor: 25.391

Review 3.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

4.  Effect of single point mutations in a form of systemic amyloidosis.

Authors:  Manikanthan Bhavaraju; Ulrich H E Hansmann
Journal:  Protein Sci       Date:  2015-07-14       Impact factor: 6.725

5.  Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance.

Authors:  Mitchell H Rosner; Amaka Edeani; Motoko Yanagita; Ilya G Glezerman; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

6.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Authors:  Tomer Mark; David Jayabalan; Morton Coleman; Roger N Pearse; Y Lynn Wang; Richard Lent; Paul J Christos; Joong W Lee; Yash P Agrawal; Susan Matthew; Scott Ely; Madhu Mazumdar; Ethel Cesarman; John P Leonard; Richard R Furman; Selina Chen-Kiang; Ruben Niesvizky
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

7.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

Review 8.  Treatment of myeloma: cure vs control.

Authors:  S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

Review 9.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

10.  Familial multiple myeloma: report on two families and discussion of screening options.

Authors:  Erica H Gerkes; Mirjam M de Jong; Rolf H Sijmons; Edo Vellenga
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.